Is sell-side coverage objective?

Hi, I'm on the VC side with little exposure to public markets or equity research. Heard a public markets investor tell me they aggregate coverage from different sell-side analysts and use that to give them direction.

Question for those of you in equity research:

1. How objective is your coverage? (my understanding coverage exists for marketing and not a critical analysis)

2. How do you decide on which companies to cover? (is this purely driven by front-office requirements, or is there an overarching strategy to have sufficient coverage within a given market?)

 
Most Helpful

1) ER is all marketing at the end of the day with some objective analysis sprinkled in here and there.

2) Coverage is based on a few things, but I think its mostly about (a) buy side interest and (b) just covering the biggest names in your sector. The whole point is to get client interaction, so covering some small cap company no one cares about doesn’t benefit SS much.

 

Correct. Equity Research isn't meant to be a stock-pick (despite the "recommendations" component). It's a tool used to generate business for other lines of the company...i.e. does it help get an IB mandate if you can market the stock post IPO and generate liquidity, do you have access to the management team so a hedge fund is willing to trade through your brokerage to get access, etc. If there's no interest in the name, there's no reason to cover it. 

 

Ignore my title I work in ER at a boutique. The commenters above refer to ER at BBs, which isn't respective of the entire industry. ER reports at BBs are largely rubbish and for market SS ER at boutiques think ISI (before EVR acquisition), TPH (before PWP acquisition), Cowen (Before TD), Berenberg, Wolfe, etc. actually publish quality research that people that invest in the public market actually read and take seriously.

Personally, I'd never take SS ER seriously. Just recently, an ER analyst at a BB that had a sell rating on a company magically changed his rating right as the IBD announced that they were working with that same company. I wonder why

 

Depends on the type of firm. Excluding the reputable boutiques who monetize only on client subscriptions, 

1. How objective is your coverage? Not objective at all

2. How do you decide on which companies to cover? Combination of what the analyst wants to cover, what the firm pressures them to cover for revenue purposes (they gonna rate them "SELL" right? Sike), and what they must cover as a result of being on the IPO

 

I don’t understand this question. Why would some notion of “objectivity” ever be the goal with research anywhere? 
 

You add value through differentiated research and perspective, which naturally requires an opinion or subjective view. Nobody (except for a newcomer to the name) calls the guy who regurgitates the “house view” from IR.

 

I think it depends heavily on your analyst. I’d like to think that my team does a fair amount of fundamental research.

My lead analyst has had very successful careers as an entrepreneur and on the buy side. As a result, he is in his seat rn purely bc he loves it — he doesn’t care about appeasing corporates or driving banking revenues. Obviously we soften language, but I can say that 100% of the content we have published in the ~18 months I’ve been here has been solely our view.

As for the companies we cover; our “core” coverage is the companies that clients are most interested in. When we pick up coverage it’s either 1. Banking is driving it 2. Clients are asking us abt it…deal flow has been slow so it’s been mostly the second one since I started working.

 

Eaque enim fuga sint qui. Ex exercitationem numquam sapiente molestias. Tenetur corrupti officia ullam inventore cum ratione.

Accusantium quia nulla rerum quia laudantium. Alias ullam itaque quis voluptatem maiores et.

Qui pariatur voluptas exercitationem. Eligendi modi non reprehenderit qui est asperiores ipsa. Aspernatur consequatur libero ut.

Odio nemo non est dolorem dolore. Quia dignissimos nesciunt ex et voluptas. Ipsa nemo officia omnis et. Velit rem dignissimos dolores veniam.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (87) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
kanon's picture
kanon
98.9
9
Linda Abraham's picture
Linda Abraham
98.8
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”